Company / Working Capital
Roivant Sciences Working Capital History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$6.5B
FY2024
5-year range
$1.5B / $6.5B
FY2021-FY2024
Trend
+323.6%
vs FY2023
Sector context
#6 of 213
Health Care
What the data says
Working Capital changed +324% YoY in FY2024, a notable deviation from the 3-year average annual change of +100%.
Based on SEC 10-K filings.
$6.5B in FY2024 with a 3-year CAGR of +48.7%. Top quartile in the Health Care sector.
Improved from $2.0B to $6.5B over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +48.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 213This company $6.5B Sector average $934.6M
▼
+591.8% above sector average
Key checks
Key Insights
- 3-year CAGR of +48.7%, indicating consistent growth.
- In FY2024, working capital increased 323.6% year-over-year.
- Ranks #6 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $6.5B | +323.6% |
| FY2023 | $1.5B | -22.2% |
| FY2022 | $2.0B | -0.3% |
| FY2021 | $2.0B | - |
| FY2020 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026